Home   |   About Us   |   Research & Development   |   Clinical Trials   |   News   |   Contact Us 

About Glycadia  |  Directors

Margo Cohen, MD, President and Chief Scientific Officer

Dr. Cohen is President and Chief Scientific Officer, Glycadia Pharmaceuticals. [See full bio under Officers]

Arthur Rubenstein, MD, MBBCh

Dr. Rubenstein is Executive Vice President of the University of Pennsylvania Health System and Dean of the University of Pennsylvania School of Medicine. Previously, Dr. Rubenstein served as Dean of the Mount Sinai School of Medicine, where he also was the Gustave L. Levy Distinguished Professor, and as Chairman of the Department of Medicine at the University of Chicago Pritzker School of Medicine, where he also was the Lowell T. Coggeshall Distinguished Service Professor of Medical Sciences. Dr. Rubenstein is internationally recognized for clinical expertise and groundbreaking research in diabetes. His numerous awards and prizes include the Banting Medal from the American Diabetes Association, the David Rumbough Scientific Award from the Juvenile Diabetes Association, the Robert H. Williams Distinguished Chair of Medicine, the highest honor of the Association of Professors of Medicine, and the John Phillips Memorial Award from the American College of Physicians. Author of more than 350 publications, Dr. Rubenstein has held several editorial advisory positions and has served as President of the Association of Professors of Medicine and of the Association of American Physicians, and on study sections of the National Institutes of Diabetes, Digestive and Kidney Diseases. He is a member of the Institute of Medicine of the National Academy of Sciences.

Milton D. Dresner

Mr. Dresner Is a founding partner of The Highland Companies, a diversified real estate development and management organization active in housing communities and industrial real estate. Mr. Dresner serves on the Advisory Board of Corinthian Capital and has previously served on the Board of Directors of BioTime, Childtime Child Care, the Fairchild Corporation, Flagship Federal Savings Bank, the Hudson General Corporation, and the Marco Polo Pure China Fund. Mr. Dresner is active in the New York investment community, and is an investor in over 25 hedge funds.

Kevin Furlong

Mr. Furlong is CEO and a Director of the Dresner Foundation, which supports medical research and youth programs. Formerly a partner in a Michigan firm, Mr. Furlong is a certified public accountant and has over thirty years of experience working in real estate development and management fields.

Aaron B. Honigman

Mr. Honigman is the managing member of Laurel Biotech, which invests in the biopharmaceutical Industry, and is an investor and manager of the Honigman family enterprises. Mr. Honigman has over 20 years of experience in investment, real estate development and health care fields.

 

 

 




Glycadia Pharmaceuticals          1880 JFK Blvd, Suite 200          Philadelphia, PA 19103
Tel 215.557.8021          Fax 215.557.8053



Developing safe and effective treatments for diabetic complications.™